Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib.

Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib. Abstract Text:

Nielka P van Erp,Hans Gelderblom,Mats O Karlsson,Jing Li,Ming Zhao,Jan Ouwerkerk,Johan W Nortier,Henk-Jan Guchelaar,Sharyn D Baker,Alex Sparreboom,Nielka P van Erp,Hans Gelderblom,Mats O Karlsson,Jing Li,Ming Zhao,Jan Ouwerkerk,Johan W Nortier,Henk-Jan Guchelaar,Sharyn D Baker,Alex Sparreboom,

PURPOSE: To evaluate the effects of ritonavir, a potent inhibitor of CYP3A4, on the steady-state pharmacokinetics of imatinib. EXPERIMENTAL DESIGN: Imatinib pharmacokinetics were evaluated in cancer patients receiving the drug for at least 2 months, after which ritonavir (600 mg) was administered daily for 3 days. Samples were obtained on the day before ritonavir (day 1) and on the third day (day 4). The in vitro metabolism of imatinib with or without ritonavir and the effect of imatinib on 1-OH-midazolam formation rate, a probe for CYP3A4 activity, were evaluated with human CYP3A4 and pooled liver microsomes. RESULTS: In 11 evaluable patients, the geometric mean (95% confidence interval) area under the curve of imatinib on days 1 and 4 were 42.6 (33.0-54.9) mug.h/mL and 41.2 (32.1-53.1) mug.h/mL, respectively (P = 0.65). A population analysis done in NONMEM with a time-dependent covariate confirmed that ritonavir did not influence the clearance or bioavailability of imatinib. In vitro, imatinib was metabolized to the active metabolite CGP74588 by CYP3A4 and CYP3A5 and, to a lesser extent, by CYP2D6. Ritonavir (1 mumol/L) completely inhibited CYP3A4-mediated metabolism of imatinib to CGP74588 but inhibited metabolism in microsomes by only 50%. Imatinib significantly inhibited CYP3A4 activity in vitro. CONCLUSION: At steady state, imatinib is insensitive to potent CYP3A4 inhibition and relies on alternate elimination pathways. For agents with complex elimination pathways that involve autoinhibition, interaction studies that are done after a single dose may not be applicable when drugs are administered chronically.

Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib. Publishing Authors By Initials

NP van Erp,H Gelderblom,MO Karlsson,J Li,M Zhao,J Ouwerkerk,JW Nortier,HJ Guchelaar,SD Baker,A Sparreboom,NP van Erp,H Gelderblom,MO Karlsson,J Li,M Zhao,J Ouwerkerk,JW Nortier,HJ Guchelaar,SD Baker,A Sparreboom,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Clinical cancer research : an official journal of

VOLUME: 13

Page Numbers: 7394-400

Journal Abbreviation: Clin. Cancer Res.

ISSN: 1078-0432

DAY: 15

MONTH: Dec

YEAR: 2007

Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9502500

Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib.

AFFILIATION: Authors' Affiliations: Departments of Clinical Pharmacy and Toxicology and Clinical Oncology, Leiden University Medical Center, Leiden, the Netherlands.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib Related Publications

• Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel.
• Determination of paclitaxel in human plasma following the administration of Genaxol or Genetaxyl by liquid chromatography/tandem mass spectrometry.
• Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometry.
• Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib.
• Inhibition of imatinib transport by uremic toxins during renal failure.
• Interaction of Cisplatin with the human organic cation transporter 2.
• Interaction of imatinib with human organic ion carriers.
• Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.
• Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100.
• Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients.
• Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy.
• Peripheral neuropathy induced by Paclitaxel: recent insights and future perspectives.
• Pharmacogenomic importance of ABCG2.
• Systematic review on the use of systemic anticancer therapy in renal-impaired gynecological cancer patients.
• Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics.